What Are Peripheral Blood Mononuclear Cells (PBMCs)?

Peripheral blood mononuclear cells, universally abbreviated as PBMCs, are the immune cells in your blood that have a single round nucleus. The group includes lymphocytes (T cells, B cells, and natural killer cells) and monocytes, and it excludes the far more numerous red blood cells, platelets, and multi-lobed granulocytes like neutrophils. A simple blood draw followed by a density-based separation step can yield millions of these cells, which is why PBMCs have become the default starting material for an enormous range of immunology research, vaccine monitoring, cell therapy manufacturing, and disease diagnostics. Their accessibility from a routine venipuncture, combined with the fact that they carry a remarkably detailed record of a person’s immune status, makes them one of the most studied biological specimens in modern medicine.

What Is Actually in a PBMC Sample

In a healthy younger adult, roughly 85–90% of PBMCs are lymphocytes and about 10–15% are monocytes. Among the lymphocytes, T cells dominate, with CD4-positive (“helper”) and CD8-positive (“killer”) T cells making up the largest share. B cells and natural killer (NK) cells round out the lymphocyte fraction. Large-scale single-cell sequencing studies have refined this picture considerably: one project profiling cells from 120 individuals identified six main cell types within PBMCs, including B cells, CD4-positive and CD8-positive T cells, monocytes, NK cells, and dendritic cells, with most of those further divided into subtypes like naïve versus memory T cells, classical versus non-classical monocytes, and dim versus bright NK cells.¹ In practice, a “PBMC sample” can also contain a small number of contaminating platelets or granulocytes, and those contaminants tend to increase if the isolation isn’t handled quickly or carefully.

The proportions are not fixed. They shift with age, infection, autoimmune disease, cancer, and even time of day. That variability is precisely what makes PBMCs so informative: measuring how the cell mixture changes from its baseline tells clinicians and researchers what the immune system is doing.

How PBMCs Are Separated from Whole Blood

The workhorse method for isolating PBMCs is density-gradient centrifugation, most commonly using a product called Ficoll-Hypaque. The principle is straightforward: whole blood is layered on top of a solution with a carefully chosen density, then spun in a centrifuge. Red blood cells and granulocytes are heavier and sink through the solution. Platelets and plasma stay on top. PBMCs, whose density falls between the two, collect in a visible band at the interface, where they can be pipetted off.² The entire process takes under an hour and can be performed with standard laboratory equipment, which is a big part of why PBMCs became so central to immunology research in the first place.

Newer microfluidic devices are beginning to challenge Ficoll as the default. One system uses tiny ridges inside a chip to sort lymphocytes away from monocytes based on differences in cell stiffness and size, without any chemical separation medium at all.³ Another microfluidic platform demonstrated a roughly 48% increase in total cell recovery and a 77% increase in T cell recovery compared to a conventional automated system, while also dramatically reducing platelet contamination.⁴ For cell therapy manufacturing, where you want every viable T cell you can get, that kind of improvement matters.

Why Collection Details Change the Result

PBMCs seem like a simple thing to collect: draw blood, spin it, harvest the cells. In reality, several seemingly minor choices during collection and processing have outsized effects on what you end up with. Researchers designing clinical trials learn this the hard way.

The anticoagulant used in the blood collection tube is one such choice. Blood drawn into heparin tubes loses about 38% of its T cells during the isolation process compared to blood drawn into EDTA tubes, and the loss hits certain memory T cell subsets particularly hard.⁵ On the other hand, PBMCs isolated from EDTA-anticoagulated blood show higher capacity to produce certain signaling molecules when stimulated in the lab compared to PBMCs from heparinized blood.⁶ Neither anticoagulant is universally “better”; the right choice depends on which downstream assays you plan to run. But if a study mixes tubes without accounting for the difference, the data can be misleading.

Timing is just as consequential. When blood sits at room temperature before PBMCs are isolated, granulocyte contamination starts climbing after about 24 hours, and gene expression patterns begin drifting away from the freshly processed baseline.⁷ NK cell viability takes a hit if isolation is delayed beyond 20 hours, and the resulting cells are less robust after freezing and thawing.⁸ For a single-site research study, getting blood to the lab quickly is manageable. For a multinational clinical trial with dozens of collection sites, shipping logistics can make or break data quality. That is why most large trials now specify strict processing windows.

Freezing PBMCs Without Losing Function

The ability to freeze PBMCs and thaw them months or years later is essential for research that compares samples collected at different time points, or for banking cells to use in future therapies. The standard approach involves suspending the cells in a mixture containing a cryoprotectant, typically DMSO (dimethyl sulfoxide), along with a protein supplement like fetal bovine serum or albumin. The cells are then cooled slowly, usually at about one degree per minute, before being transferred to liquid nitrogen storage.

Optimized protocols achieve PBMC recovery above 83% and viability above 98% after thawing.⁹ One study tested five different cryoprotective solutions head to head and found that all produced similar survival rates of around 81%, though that was still significantly lower than fresh samples, which averaged about 94% viability.¹⁰ The reassuring finding for researchers is that the cells retain their functional identity after freezing: both CD4-positive and CD8-positive T cells preserved their ability to produce key signaling molecules in response to stimulation, and their cytokine signatures remained stable.¹¹¹²

Where cryopreservation does cause some loss is in cell-killing activity. NK cells and certain engineered killer cells derived from frozen PBMCs showed significantly lower ability to destroy tumor cells compared to those derived from fresh samples.¹⁰ This is a practical consideration for any application where direct cytotoxic function is the endpoint.

PBMCs in Infectious Disease Research

Some of the most consequential uses of PBMCs have come from HIV research. The virus primarily infects CD4-positive T cells, many of which circulate as PBMCs. When a person starts antiretroviral therapy and their viral load drops below detection in standard blood tests, the virus does not actually disappear. It hides as silent DNA integrated into the genomes of resting memory CD4-positive T cells, forming what researchers call a latent reservoir.¹³ PBMCs are the primary way researchers access and study this reservoir, because the infected cells can be isolated, cultured, and coaxed into revealing whether they carry replication-competent virus.¹⁴

Mapping the reservoir has also produced surprises. One study found that a relatively obscure T cell subtype, called Vδ2 cells, harbors latent HIV at unexpectedly high frequency. In 14 out of 18 patients on long-term antiretroviral therapy, replication-competent virus could be recovered from highly purified Vδ2 cells.¹⁵ Findings like this, made possible by detailed work on PBMC subpopulations, reshape how scientists think about what it would take to cure the infection.

Beyond HIV, PBMC-based single-cell sequencing has been used to profile immune responses in herpes zoster (shingles), mapping how immune cell populations shift between active disease and recovery by analyzing tens of thousands of individual cells at once.¹⁶

Reading the Immune System in Cancer and Autoimmune Disease

PBMCs have become a kind of liquid biopsy for the immune system. In cancer, researchers are exploring whether PBMC profiles drawn from a simple blood sample can predict who will respond to immunotherapy, sparing patients the morbidity of a tissue biopsy. One study in lung cancer found that patients who had strong effector T cell and interferon-gamma signatures in their baseline PBMC samples were significantly more likely to achieve a major pathological response to combined chemotherapy and immunotherapy.¹⁷ A separate study showed that early changes in peripheral blood cell ratios, particularly the neutrophil-to-lymphocyte ratio, predicted immunotherapy outcomes better than standard tumor biomarkers like mutation burden or PD-L1 expression.¹⁸ The appeal is obvious: tracking immune dynamics through serial blood draws is far easier on patients than repeated tumor biopsies.

In autoimmune disease, PBMCs provide a window into how the immune system has gone wrong. A study of systemic lupus erythematosus found over a thousand genes with abnormal expression in patient PBMCs, with the changes clustering heavily in interferon signaling and toll-like receptor pathways. Many of the overactive genes had reduced DNA methylation, and many of the silenced genes had increased methylation, pointing to epigenetic dysregulation as a driver.¹⁹ Work like this moves beyond simply cataloging which genes are turned up or down and starts explaining the mechanisms behind autoimmune flares.

PBMCs as Raw Material for Cell Therapies

The most direct clinical use of PBMCs today is as the starting material for engineered cell therapies, particularly CAR-T cell therapy. In this process, T cells are extracted from a patient’s PBMCs, genetically modified to recognize a protein on their tumor, expanded in the lab, and then infused back into the patient. The quality of the starting PBMC sample matters enormously, and one practical question is whether you can use frozen PBMCs instead of fresh ones, since freezing allows flexibility in scheduling the complex manufacturing process.

A recent comparison found that CAR-T cells manufactured from PBMCs frozen for up to two years showed no significant differences in viability, T cell purity, or exhaustion markers compared to CAR-T cells made from fresh PBMCs.²⁰ There were slight reductions in how quickly the frozen-origin cells proliferated, but the differences were not statistically significant. This is good news for the logistics of cell therapy, which often requires collecting cells weeks or months before they are needed.

PBMCs have also become a preferred source for generating induced pluripotent stem cells, or iPSCs. These are cells that have been reprogrammed back to an embryonic-like state, from which they can theoretically become any cell type in the body. Because PBMCs can be obtained from a simple blood draw rather than a skin biopsy, they offer a less invasive path to patient-specific stem cells. Researchers have shown that PBMC-derived iPSCs express the expected markers of pluripotency and can differentiate into all three embryonic germ layers.²¹²² More recently, a strategy to reprogram PBMCs directly into mesenchymal stromal cells, which are used in regenerative medicine and anti-inflammatory therapies, was demonstrated using a non-integrating vector system that avoids permanently altering the cell’s genome.²³

How Aging Reshapes the PBMC Landscape

If you compare PBMCs from a 25-year-old and an 80-year-old, the differences are striking. The overall balance between lymphocytes and myeloid cells (monocytes and their relatives) shifts with age. In younger adults, the ratio is roughly 86% lymphocytes to 14% myeloid cells. In extremely long-lived individuals, that shifts to about 75% lymphocytes and 25% myeloid cells.²⁴ The lymphocyte compartment itself changes composition: naïve T cells and B cells decline, while memory T cell subsets accumulate.²⁵ NK cells expand, and monocyte-to-lymphocyte ratios rise.²⁶

These age-related shifts are not just academic bookkeeping. They underlie the well-known decline in vaccine responsiveness and the increased susceptibility to infections that older adults experience. For researchers, they also mean that PBMC reference ranges are not one-size-fits-all. A PBMC profile that looks concerning in a 30-year-old may be perfectly normal in a 75-year-old, and clinical studies that do not account for age in their PBMC-based endpoints risk misinterpreting results.

PBMCs Fluctuate with Sleep, Exercise, and Time of Day

Even in a single healthy person, PBMC composition is not static from hour to hour. All major PBMC subsets follow circadian rhythms, cycling in number across the 24-hour day even when a person stays awake continuously. Sleep adds an additional layer: during nighttime sleep, the counts of monocytes, NK cells, and all lymphocyte subsets drop compared to staying awake through the night. Interestingly, the afternoon and evening after a night of sleep show a rebound, with NK cells and lymphocytes rising above the levels seen after a night of wakefulness.²⁷ Sleep also boosted T cell production of the signaling molecule IL-2, while leaving other inflammatory signals unchanged.

Acute exercise has its own rapid effects. A single bout of exercise in healthy young adults increased the number of activated CD4-positive T cells by about 79% and activated CD8-positive T cells by about 166%, while also raising the overall oxidative capacity of circulating PBMCs at the tissue level.²⁸ These transient shifts are one reason why clinical protocols for PBMC collection often specify fasting blood draws in the morning, to minimize variability introduced by meals, exercise, and circadian fluctuations. If you are comparing PBMC profiles between patients and healthy controls, the time of day the blood was drawn can matter as much as the disease itself.

Species Differences That Complicate Animal Models

Much of early immunology was built on mouse models, and PBMCs from mice are often used as stand-ins for human PBMCs in preclinical studies. But the composition of immune cells in blood differs substantially between species. A comprehensive cross-species comparison screening over 300 antibodies across humans, three non-human primate species, and mice found numerous differences in cellular phenotypes and immune signaling events, including variations in the frequency of certain T cell populations and in how granulocytes respond to bacterial antigens.²⁹ These are not minor technical quibbles. When a drug looks promising in mouse PBMCs and fails in human PBMCs, species-specific immune architecture is often the reason. Non-human primates are closer to humans immunologically but still show distinct cell subset frequencies and signaling patterns, which is why the field increasingly pushes for human PBMC data early in the development pipeline.